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Summary: Human foetal lung fibroblasts were pretreated for 24 h with the antithrombotic drug, suloctidil
(1 to 10μπιο1/1), which induced a dose-dependent increase in LDL binding, uptake and degradation. At
10 μηαοΐ/ΐ suloctidil, the respective increases in these parameters were 40%, 80% and 50%. The same treatment
also resulted in increases of 1.5 to 2-fold in the synthesis of sterols, fatty acids and triacylglycerols from
sodium acetate. In contrast, the esterification of cholesterol with oleic acid was specifically decreased by 35%
by 24 h pretreatment of fibroblasts with 10 μπιοΙ/1 suloctidil. A similar decrease of cholesterol esterification
was observed in cholesterol-laden fibroblasts. It is suggested that these effects of suloctidil on LDL processing
and cholesterol metabolism are related to the amphiphilic characteristics of the drug and to its calcium-
blocking properties.
Introduction
After binding to receptors, LDL uptake and degra-
dation by cultured fibroblasts result in repression of
endogenous cholesterol synthesis and stimulation of
cholesterol esterification (1, 2). The importance of
this pathway arises from the fact that a decrease in
LDL receptor number, as observed in familial hyper-
cholesterolaeinia (3, 4), leads to premature atheros-
clerosis. Besides the hormonal control of this pathway
by insulin (5) or epinephrine (6), it has been demon-
strated that some amphiphilic drugs, such as pheno-
thiazines (7), propranolol (8), or AY 9944 (9, 10),
stimulate the LDL receptor pathway. This effect is
probably mediated by a direct action of the drugs on
the phosphplipid bilayer.
Suloctidil (1 -(4-isopropylthiophenyl>2^-octylamino-
propanol) was originally used as an antispasmodic
agent for the treatment of cerebral and peripheral
artery insufficiencies (11, 12). Subsequently, it was
observed that this drug also inhibits platelet aggre-
gation (13, 14) and prevents experimentally induced
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thrombosis (15, 16). It was also demonstrated that
suloctidil inhibits calcium influx (17, 18), perhaps by
affecting membrane fluidity (19). Because of its am-
phiphilic character, suloctidil has the property of bind-
ing readily to cell membranes, especially to the acidic
phospholipids (20).
In this work, the effect of suloctidil on LDL binding,
internalization and degradation was investigated.
Cholesterol synthesis and esterification have been also
shown to be affected by suloctidil.
Materials and Methods
Cell culture
MRC5 (human foetal lung) fibroblasts were purchased from
Biomerieux France, and maintained in Nunc flasks with Did-
becco's medium (Gibco) supplemented with 10% foetal calf
serum (Gibco) at 37 °C, in a 5% CO2 atmosphere. For exper-
iments, cells are taken at confluency, in 35 mm Nunc Petri
dishes containing approximately 2 χ ΙΟ5 cells.
LDL preparation and labeling
LDL was prepared from normal human serum by 3 step-
ultracentrifugation at 105 000 £ in a L5.50 Beckman ultracen-
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trifugc, according to Havel et al. (21). The LDL was taken as
the 1.024-1.050 kg/1 density fraction. 125Iodine labeling was
performed by the method of Bilheimer et al. (22).
Effect of suloctidil on LDL binding, uptake and deg-
radat ion
For maximal induction of LDL receptors, cells were pretreated
for 24 h with suloctidil (Searle Lab.) in ethanol solution (final
ethanol concentration 0.5%) in medium devoid of serum, sup-
plemented with 2% serum substitute Ultroser G (Industries
Biologiques Francaises). Cells were then washed twice, and
LDL binding, uptake and degradation studied according to
Goldstein & Brown (4). Incubations were performed for 2 h at
4°C for binding studies, and 4 h at 37 °C for uptake and
degradation studies, in 0.5 ml Ham F10, 10 mmol/1 Hepes pH
7.4 medium. The final concentration of LDL in the incubation
medium was 10 mg/1. After incubation, cells were washed 4
times with a phosphate-buffered solution (pH 7.4), harvested
with a rubber policeman and centrifuged for 5 min at 400 g.
The radioactivity associated with the pellet was measured with
a Packard 256 gamma-counter. For the study of [125I]LDL
degradation, the incubation medium (0.5 ml) was removed
before cell washing and 0.25 ml of 500 g/1 trichloroacetic acid
was added. The samples were maintained at room temperature
for 10 min. The precipitate was centrifuged for 10 min at 4000 g.
Ten microlitres of 400 g/ΪΚΙ and 50 μΐ of 300 g/kg H2O2 were
then added to 0.5 ml of the supernatant. After mixing, the
samples were maintained for 30 min at 4°C, then extracted
with 2 ml chloroform, and radioactivity counted on 0.2 ml of
the upper phase. Results are calculated in ng LDL per mg of
cell protein and then expressed as fraction of control value.
Protein was determined by the method of Lowry et al. (23).
Effect of suloctidil on cholesterol metabolism
Experiments were performed with sodium [l-14C]acetate (1.77
GBq/mmol, CEA France) or [l-14C]oleic acid (1.92 GBq/mmol,
Amersham). Cells were pretreated for 24 h with suloctidil. After
evaporation to dryness in a nitrogen stream, oleic acid was
resuspended for 15 min at 37 °C in a fatty acid-free human
serum albumin solution 0.2 g/1. Radioactive sodium acetate
(1.11 GBq/1) or oleic acid (18.5 MBq/1) was then added and a
further 4 h incubation performed. Cells were washed three times
and lipid analysis performed by thin layer chromatography
after direct application of the cell suspension on silica gel plates,
using a modification of the method described by Dosado et al.
(24). Neutral lipids were separated by the solvent system hex-
ane/diethylether/acetic acid 70/30/2 (by vol.) and phospholipids
by the solvent system chloroform/methanol/acetic acid/H2O 50/
30/8/4 (by vol.). After autoradiography, the radioactive spots
were cut out and counted by liquid scintillation. Results are
expressed in pmol of precursor incorporated per mg cellular
protein.
Results
The effects of suloctidil on LDL binding, uptake and
degradation are shown in figure 1, showing that the
three parameters were increased after a 24 h treatment
with suloctidil. However, uptake was somewhat more
sensitive to suloctidil than binding and degradation.
At 10 μιηοΐ/ΐ, suloctidil induced a 1.4, 1.8 and 1.5
fold increase in binding, uptake and degradation,
respectively. At concentrations higher than 10 μτηοΐ/ΐ,
a cytotoxic effect of suloctidil was observed in our
system.
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Fig. 1. Effect of suloctidil on LDL binding (o), uptake (V)
and degradation (a) by cultured human fibroblasts.
Cells were treated for 24 h with suloctidil in ethanol
solution (final ethanol concentration 0.5%). Binding,
uptake and degradation were then measured hi the
absence of the drug with 1Q mg/1 [^IJLDL 3.33-5.0
Bq/ng. Abscissa = suloctidil concentration (mol/1). Or-
dinate: Fraction of control value. The absolute values
(LDL, ng/mg protein) were: 32 ± 3 for binding,
194 ± 11 for uptake and 297 ± 19"" for degradation.
Means of 4 determinations ± S. D.
Sterol synthesis from sodium acetate and cholesterol
esterification with oleic acid were also studied after a
24 h pretreatment with suloctidil. The results in table
1 demonstrate that suloctidil caused a dose-dependent
stimulation of sterol synthesis. At 10 μιηοΐ/ΐ, sterol
synthesis was about 1.8 fold increased. However, it
must be noted that this effect was not specific: fatty
acid and triacylglycerol synthesis were also increased
in the presence of suloctidil, albeit to a lesser extent.
As for cholesterol esterification, the results in table 2
indicate that the incorporation of oleic acid into dbw>
lesteryl esters was notably decreased in the presence
of suloctidil; at 10 μιτηοΐ/ΐ, cholesterol esterification
was about one third ofthat in the controls. This effect
appeared to be specific, since the incorporation into
triacylglycerols and phospholipids, taken as the inter-
nal control, were not affected.
In another set of experiments, oleic acid incorporation
into cholesteryl esters was measured in cholesterol-
laden cells (tab. 3). It can be seen that in the presence
of cholesterol 25 g/i in ethanol solution, the incor^
poration into cholesteryl esters, which reflects the
activity of the enzyme acylcoenzyme A : 'Cholesterol-
Oacyl trafisfefase was about 4-fold higher than in
non-laden cells. Moreover, the decrease xif cholesterol
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Tab. 1. Effect of suloctidil on lipid synthesis from sodium acetate.
Addition
Control (Ethanol, volume fraction 0.005)
Suloctidil (in ethanol, volume fraction 0.005)
1 μιηοΐ/ΐ
5 μπιοΙ/1
10 μιηοΐ/l
Sodium acetate (pmol/mg protein) incorporated into
Sterols Fatty acids Triacylglycerols
375 ± 50 1280 ± 180 1475 ± 230
520 ± 140* 1560 + 150 1620 + 265
580 + 115** 1870 + 190** 1900 + 240*
660 ± 95** 2050 + 210** 2110 + 250*
Phospholipids
22450 ± 3650
24420 ± 3950
25610 + 4120
28550 ± 3510*
For maximal induction of sterol synthesis, cells were pretreated for 24 h in serum-free medium, supplemented with the serum
substitute Ultroser G. Sodium [l-14C]acetate (1.11 GBq/1) was then added and a further 4 h incubation performed. Lipid separation
was performed by thin layer chromatography. Means of 3 experiments ± S. D.
* = p < 0.05; ** = p < 0.01
Tab. 2. Effect of suloctidil on oleic acid incorporation into
lipids.
Tab. 3. Effect of suloctidil on oleic acid incorporation into
cholesteryl esters in cholesterol-laden fibroblasls.
Addition Oleic acid (pmol/mg protein) incorpora-
ted into
Control
(ethanol, volume
fraction 0.005)
Suloctidil (in
ethanol, volume
fraction 0.005)
1 μπιοΐ/ΐ:
5 μπιοΙ/1:
10 μπιοΐ/l:
Cholesteryl
esters
240 ± 30*
170 ± 25*
130 + 20**
85 + 15***
Triacyl-
glycerols
1610 ± 250
1775 ± 295
1530 ± 200
1720 ± 300
Phospho-
lipids
8330 + 910
8450 + 880
9120 + 870
9210 + 920
Cells were pretreated for 24 h with suloctidil in medium sup-
plemented with 10% foetal calf serum for induction of the
enzyme acyl Coenzyme A : cholesterol acyl transferase. [1-
14C]oleic acid (18.5 MBq/1) was then added and a further 4 h
incubation performed. Lipid analysis was performed by thin
layer chromatography. Means of 3 determinations + S. D.
* = p < 0.05; ** = p < 0.01; *** = p < 0.001 by Student
t-test.
esterification induced by suloctidil in non-laden cells
was again observed. This is of interest in view of the
fact that io atherosclerotic plaques, cholesterol is de-
posited in foam cells mainly in the esterified form.
Incubation
Medium
Control 1
(Ethanol, volume
fraction 0.005)
Control 2
(Ethanol, volume
fraction 0.01)
Cholesterol 25 mg/1
(Ethanol, volume
fraction 0.005)
Suloctidil 10 μπιοΙ/1
(Ethanol volume
fraction 0.005)
Cholesterol 25 mg/1
+ Suloctidil 10 μπιοΙ/1
(Ethanol, volume
fraction 0.01)
Oleic acid
(pmol/mg protein)
incorporated
into cholesteryl
esters
112± 9
106 ± 10
391 ± 32
28 ± 4***
51 ± 4*
Cells were pretreated for 24 h with suloctidil in the presence or
absence of cholesterol in ethanol solution. [l~14C]oleic acid
(9.25 MBq/1) was then added and a further 4 h incubation
performed. Means of 3 determinations + S. D.
*** = p < 0.001 by Student t-test.
Discussion
Suloctidil induced an increase f LDL binding by
cultured human fibroblasts. This increase might be
due to modification of either the number of LDL
receptors or of the affinity of LDL receptors. Previous
work from our laboratories demonstrated that the
effect of amphiphilic drugs on LDL binding is rapid
(7) and due to an increase in LDL receptor number
(10), probably by unmasking a cryptic pool of un-
available receptors. It is most likely that the amphi-
philic drug, suloctidil, exerts its effect on LDL binding
by this mechanism.
After binding, LDL receptors are internalized in
coated vesicles, which give rise to endosomes (25).
Endosomes then reach the Golgi apparatus (26) and
finally the lysosomes, where degradation is achieved.
The fact that suloctidil increases LDL uptake and
degradation suggests that some of these processes are
affected by the drug, either directly after intercalation
in the phospholipid bilayer (20) or indirectly by its
effect on calcium influx (17, 18). It is of note that a
similar effect on LDL processing was recently de-
scribed by Stein et al. with another calcium antago-
nist : verapamil (27).
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A stimulation of sterol synthesis and an inhibition of
cholesterol esterification were observed with sulocti-
dil. These results are the reverse of what could be
expected if suloctidil only acts through its ability to
increase LDL processing. Thus, the effects of suloc-
tidil on cholesterol metabolism are independent of its
action on LDL metabolism. Further evidence arises
from the fact that for the study of sterol synthesis,
suloctidil was introduced in serum-free medium,
which thus contained no LDL. It must be noted that
the activities of 3-hydroxy-3-methyl-glutaryl-coen-
zyme A reductase and acylcoenzyme A : cholesterol-
O-acyl-transferase have been shown to be modulated
by the physico-chemical properties of cell membranes,
especially by membrane microviscosity (28, 29). The
stimulation of lipid synthesis together with the specific
inhibition of cholesterol esterification have also been
observed with other amphiphilic drugs such as pro-
prariolol and phenothiazines (10). However, the cal-
cium-blocking properties of the drug suloctidil might
also be involved, since Ranganathan et al. (30) re·-
ported that calcium-blocking agents such as verapamil
or diltiazem also stimulate sterol synthesis. Thus, the
observed effects of suloctidil on LDL processing and
cholesterol metabolism might be related to both its
amphiphilic characteristics and its calcium^blocking
properties.
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